Novartis Ag ADR
LICHTSTRASSE 35BASEL V8 CH 4056 CHE
P: 41-61-324-1111
F: +41 613247826
http://www.novartis.com
Profile
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Key Executives
Name | Title |
---|---|
Harry Kirsch | CFO |
Vasant Narasimhan | CEO |
Steffen Lang | President, Divisional |
Klaus Moosmayer | Chief Compliance Officer/Chief Risk Officer/Other Executive Officer |
Shreeram Aradhye | Chief Medical Officer/President, Divisional |
Victor Bulto | President, Geographical |
Karen L. Hale | Chief Legal Officer |
Robert Kowalski | Other Executive Officer |
Aharon Gal | Chief Strategy Officer/Other Executive Officer |
Fiona Marshall | President, Divisional |
Patrick Horber | President, Divisional |